CTLA4 and neoplasm: Our study expands previous evidence on the immunoregulatory and anti-tumor activity of demethylating agents, including guadecitabine, when used either alone or in combination with anti-CTLA-4 in pre-clinical immunocompetent mouse models [30, 31, 41, 42].